Key result
Recent advancements in gene editing technologies, particularly prime editor proteins, have improved editing efficiency and reduced off-target effects for treating genetic and hematological disorders.
Why the study?
Recent advancements in protein and RNA engineering and delivery methods have addressed critical issues in gene editing, prompting a comprehensive overview of these innovations and their therapeutic potential.
Recent advancements in prime editing and base editing technologies offer expanded capabilities for precise genomic modifications, with significant potential for treating genetic and hematological disorders.
Gene editing refinements may expand options for inherited cardiovascular disorders; leaves open clinical validation in prospective trials.
The advent of gene editing has significantly advanced the field of medicine, opening new frontiers in the treatment of genetic disorders, cancer, and infectious diseases. Gene editing technology remains a dynamic and promising area of research and development. Recent advancements in protein and RNA engineering within this field have addressed critical issues such as imprecise edits, poor editing efficiency, and off-target effects. Advancements in delivery methods have allowed the achievement of therapeutic or even selection-free gene editing efficiency with reduced toxicity in primary cells, thereby enhancing the safety and efficacy of gene manipulation. This progress paves the way for transformative changes in molecular biology, medicine, and other fields. This review provides a comprehensive overview of the advancements in gene editing techniques, focusing on prime editor proteins and their engineered variants. It also explores alternative systems that expand the toolkit for precise genomic modifications and highlights the potential of these innovations in treating hematological disorders, while also discussing the limitations and challenges that remain.
No takes yet. Share an insight, caveat, or question.
Abhijith et al. (2025) conducted a review in Genetic disorders, cancer, infectious diseases, and hematological disorders. Gene editing technologies was evaluated. Recent advancements in gene editing technologies, particularly prime editor proteins, have improved editing efficiency and reduced off-target effects for treating genetic and hematological disorders.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: